Subscribe for the newsletter
Sign in
Articles
Expert Interviews
Roundtable
Press Releases
Videos
The Road To Series
Market Research
Thought Leaders
More
Discovery
Small Molecules
Biologics
Advanced Therapies
Manufacturing
Supply Chain
Clinical Trials
Technologies
Financing
Prostate Specific Antigen
Sort By
Newest First
1 / 1
1 / 1
Clinical Trial
ERLEADA™ Significantly Reduced Risk of Prostate Specific Antigen (PSA) Progression in Patients with Non-Metastatic Castration-Resistant Prostate Cancer
Janssen Pharmaceutical Companies
PR-M05-18-NI-086
May 23, 2018
